Division of Pulmonology, University Hospital Zurich, Rämistrasse 100, CH-8091 Zurich, Switzerland.
Respir Res. 2014 Apr 16;15(1):47. doi: 10.1186/1465-9921-15-47.
Pulmonary hypertension is an "umbrella term" used for a spectrum of entities resulting in an elevation of the pulmonary arterial pressure. Clinical symptoms include dyspnea and fatigue which in the absence of adequate therapeutic intervention may lead to progressive right heart failure and death. The pathogenesis of pulmonary hypertension is characterized by three major processes including vasoconstriction, vascular remodeling and microthrombotic events. In addition accumulating evidence point to a cytokine driven inflammatory process as a major contributor to the development of pulmonary hypertension.This review summarizes the latest clinical and experimental developments in inflammation associated with pulmonary hypertension with special focus on Interleukin-6, and its role in vascular remodeling in pulmonary hypertension.
肺动脉高压是一个“伞形术语”，用于描述一系列导致肺动脉压力升高的实体。临床症状包括呼吸困难和疲劳，如果没有足够的治疗干预，可能会导致右心衰竭和死亡。肺动脉高压的发病机制以三个主要过程为特征，包括血管收缩、血管重塑和微血管血栓形成事件。此外，越来越多的证据表明，细胞因子驱动的炎症过程是肺动脉高压发展的主要因素。本综述总结了与肺动脉高压相关的炎症的最新临床和实验进展，特别关注白细胞介素-6及其在肺动脉高压血管重塑中的作用。
